BR9914266A - Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego - Google Patents

Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego

Info

Publication number
BR9914266A
BR9914266A BR9914266-0A BR9914266A BR9914266A BR 9914266 A BR9914266 A BR 9914266A BR 9914266 A BR9914266 A BR 9914266A BR 9914266 A BR9914266 A BR 9914266A
Authority
BR
Brazil
Prior art keywords
compounds
processes
preparation
heterocycles
drugs containing
Prior art date
Application number
BR9914266-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Wendelin Frick
Reinhard Kirsch
Heiner Glombik
Hubert Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9914266A publication Critical patent/BR9914266A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9914266-0A 1998-10-02 1999-09-18 Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego BR9914266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845402A DE19845402B4 (de) 1998-10-02 1998-10-02 Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006932 WO2000020410A1 (de) 1998-10-02 1999-09-18 Mit heterocyclen substituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
BR9914266A true BR9914266A (pt) 2001-11-06

Family

ID=7883184

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914266-0A BR9914266A (pt) 1998-10-02 1999-09-18 Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego

Country Status (21)

Country Link
US (1) US6303639B1 (https=)
EP (1) EP1117661B1 (https=)
JP (1) JP2002526539A (https=)
KR (1) KR100611030B1 (https=)
CN (1) CN1150185C (https=)
AR (1) AR021843A1 (https=)
AT (1) ATE267825T1 (https=)
AU (1) AU760412B2 (https=)
BR (1) BR9914266A (https=)
CA (1) CA2346083A1 (https=)
DE (2) DE19845402B4 (https=)
DK (1) DK1117661T3 (https=)
ES (1) ES2219065T3 (https=)
HK (1) HK1040249B (https=)
HU (1) HUP0103893A3 (https=)
PL (1) PL347105A1 (https=)
PT (1) PT1117661E (https=)
RU (1) RU2219176C2 (https=)
TR (1) TR200100895T2 (https=)
WO (1) WO2000020410A1 (https=)
ZA (1) ZA200102589B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MXPA03005019A (es) 2000-12-21 2003-09-25 Avantis Pharma Deutschland Gmb Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1420826A2 (de) * 2001-08-22 2004-05-26 Aventis Pharma Deutschland GmbH Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
RU2363699C2 (ru) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
AU2011232347B2 (en) * 2010-03-24 2015-08-06 Musc Foundation For Research Development Compositions and methods for the treatment of degenerative diseases
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
US11238759B1 (en) 2015-10-29 2022-02-01 Ward-Kraft, Inc. Single ply wristband with printable coating
US11232719B1 (en) 2019-09-04 2022-01-25 Ward-Kraft, Inc. Single ply wristband with printable coating
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
USD988404S1 (en) 2020-02-14 2023-06-06 Rekon, Llc Wristband label form with single strap wristbands
USD941917S1 (en) 2020-02-18 2022-01-25 Ward-Kraft, Inc. Combination wristband label form with extender
USD967253S1 (en) 2020-02-26 2022-10-18 Ward-Kraft, Inc. Wristband form with extender

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
FI892341L (fi) * 1988-06-10 1989-12-11 Hoffmann La Roche Propanolaminderivat.
DE19704243A1 (de) * 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
EP0869121B1 (de) * 1997-04-04 2004-06-09 Aventis Pharma Deutschland GmbH Hypolipidämische Propanolaminderivate

Also Published As

Publication number Publication date
US6303639B1 (en) 2001-10-16
JP2002526539A (ja) 2002-08-20
HUP0103893A3 (en) 2002-10-28
ZA200102589B (en) 2002-02-27
PL347105A1 (en) 2002-03-25
AU6192599A (en) 2000-04-26
KR100611030B1 (ko) 2006-08-10
ATE267825T1 (de) 2004-06-15
AR021843A1 (es) 2002-08-07
WO2000020410A1 (de) 2000-04-13
HUP0103893A2 (hu) 2002-05-29
DE19845402A1 (de) 2000-04-13
HK1040249B (zh) 2005-04-01
KR20010103593A (ko) 2001-11-23
HK1040249A1 (en) 2002-05-31
CN1321154A (zh) 2001-11-07
RU2219176C2 (ru) 2003-12-20
DE59909609D1 (de) 2004-07-01
CN1150185C (zh) 2004-05-19
DK1117661T3 (da) 2004-08-30
AU760412B2 (en) 2003-05-15
DE19845402B4 (de) 2005-04-07
CA2346083A1 (en) 2000-04-13
TR200100895T2 (tr) 2001-12-21
ES2219065T3 (es) 2004-11-16
PT1117661E (pt) 2004-09-30
EP1117661B1 (de) 2004-05-26
EP1117661A1 (de) 2001-07-25

Similar Documents

Publication Publication Date Title
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR9912188A (pt) Derivados de 1,1-dióxido de benzo (b) tiepina, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BR0116325A (pt) 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
BR0116322A (pt) Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BR0116482A (pt) Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BRPI0407507A (pt) derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona, processos para sua preparação de sua aplicação como medicamento
BR9814416A (pt) "estratrienos substituìdos por 11beta-halogeno-7alfa, processos para a preparação de preparados farmacêuticos, que contêm estes estratrienos substituìdos por 11-beta-7alfa, bem como seu emprego para a preparação de medicamentos"
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BRPI9917007B8 (pt) azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR9915027A (pt) Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BR0108631A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d] tiazol, que na posição 2 portam um substituinte com uma estrutura sulfonamida ou estrutura sulfona; processos para a sua preparação e seu emprego como medicamento

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements